The USA’s Puma Biotechnology (Nasdaq: PBYI) has entered into an exclusive agreement under which Specialised Therapeutics Asia will commercialize Nerlynx (neratinib) throughout South East Asia, beginning with Australia, Singapore, Malaysia, Brunei and New Zealand.
Nerlynx was approved by the US Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy, making it the first drug to be approved for this specific indication. However, it has not been approved for commercialization in any other countries. In the USA, Nerlynx reportedly costs around $12,000 for a month’s supply.
Currently, Singapore-headquartered Specialised Therapeutics markets US biotech major (Nasdaq: CELG) Celgene’s Abraxane (nab-paclitaxel) and other oncology products in these countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze